CO6290685A2 - Compuestos de carbamoilo como inhibidores de la dgat1 190 - Google Patents

Compuestos de carbamoilo como inhibidores de la dgat1 190

Info

Publication number
CO6290685A2
CO6290685A2 CO10074457A CO10074457A CO6290685A2 CO 6290685 A2 CO6290685 A2 CO 6290685A2 CO 10074457 A CO10074457 A CO 10074457A CO 10074457 A CO10074457 A CO 10074457A CO 6290685 A2 CO6290685 A2 CO 6290685A2
Authority
CO
Colombia
Prior art keywords
ring
carbon atom
alkyl
alkoxy
atoms
Prior art date
Application number
CO10074457A
Other languages
English (en)
Inventor
Udo Bauer
Alan Martin Birch
Roger John Butlin
Clive Green
Jonas Barlind
Guy Hovland
Petra Johannesson
Alexander Noeske
Annika Ulrika Petersson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40427160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6290685(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO6290685A2 publication Critical patent/CO6290685A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

1.- Un compuesto de la fórmula (I), o una sal farmacéuticarnente aceptable, o pro-fármaco del mismo,en donde El Anillo A es 2,6-pirazindiilo, 3,5-piridindiilo o 2,6-piridindiilo, cada uno opcionalmente sustituido sobre un átomo de carbono disponible, por uno o dos sustituyentes independientemente seleccionados a partir de (1-3C)alquilo lineal, (2-3C)alquenilo, (2-3C)alquinilo, (1-2C)alcoxilo, metoximetilo, amino y ciano; X es =0 o =S; El Anillo B es 1,4-fenileno o el Anillo B es un anillo di-enlazado (excluyendo enlaces vía los mismos átomos o átomos adyacentes) seleccionado a partir de piridindiilo, furiilo, tiofendiilo, pirroldiilo, oxazoldiilo, tiazoldiilo, imidazoldiilo, isoxazoldiilo, isotiazoldiilo y pirazoldiilo; cada uno opcionalmente sustituido sobre un átomo de carbono disponible, por uno o dos sustituyentes independientemente seleccionados a partir de halo, amino, ciano, (1-4C)alquilo, (2-3C)alquenilo, (2-3C)alquinilo, (1-4C)alcoxilo y (1-4C)alcoxilo-(1-4C)alquilo; Y1 es un enlace directo entre el Anillo B y el Anillo C o Y1 es -O-, -S- o -NRa- en donde Ra es hidrógeno o (1-4C)alquilo; Y2 es -(CH2)r en donde r es 2 o 3, y Y2 está unido al mismo átomo de carbono como Y1 en el Anillo C y Y2 está unido en un átomo de carbono adyacente a Y1 en el Anillo B; n es 0 o n es 1 cuando Y1 es un enlace directo entre el Anillo B y el Anillo C y cuando el Anillo B es 1,4-fenileno y el Anillo C es (4-6C)cicloalcano, de manera que un sistema espiro-cíclico de 5- o 6-miembros es formado y el Anillo C es tri-enlazado; El Anillo C es un anillo di-enlazado (excluyendo enlaces vía los mismos átomos o átomos adyacentes) o sistema cíclico elegido a partir de (4-6C)cicloalcano, (7-10C)bicicloalcano y (8-12C)tricicloalcano cada uno opcionalmente sustituido sobre un átomo de carbono disponible, incluyendo el átomo de carbono cíclico que porta el grupo que contiene Z, por un sustituyente seleccionado a partir de hidroxilo, (1-4C)alquilo, (1-4C)alcoxilo y (1-4C)alcoxi(1-4C)alquilo;o el Anillo C es un anillo di-enlazado (excluyendo enlaces vía los mismos átomos o átomos adyacentes) seleccionado a partir de fenileno, ...
CO10074457A 2007-12-20 2010-06-21 Compuestos de carbamoilo como inhibidores de la dgat1 190 CO6290685A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1539707P 2007-12-20 2007-12-20

Publications (1)

Publication Number Publication Date
CO6290685A2 true CO6290685A2 (es) 2011-06-20

Family

ID=40427160

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10074457A CO6290685A2 (es) 2007-12-20 2010-06-21 Compuestos de carbamoilo como inhibidores de la dgat1 190

Country Status (23)

Country Link
US (2) US7994179B2 (es)
EP (1) EP2234978B1 (es)
JP (1) JP5662803B2 (es)
KR (1) KR20100099738A (es)
CN (1) CN101932562B (es)
AR (1) AR069802A1 (es)
AU (1) AU2008339570B2 (es)
BR (1) BRPI0821274A2 (es)
CA (1) CA2707660A1 (es)
CL (1) CL2008003847A1 (es)
CO (1) CO6290685A2 (es)
CR (1) CR11518A (es)
DO (1) DOP2010000192A (es)
EA (1) EA201001015A1 (es)
EC (1) ECSP10010274A (es)
ES (1) ES2535083T3 (es)
IL (1) IL206045A0 (es)
NI (1) NI201000108A (es)
NZ (1) NZ586104A (es)
PE (1) PE20091682A1 (es)
TW (1) TW200932235A (es)
WO (1) WO2009081195A1 (es)
ZA (1) ZA201003979B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2588162A1 (en) * 2004-12-14 2006-06-22 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
EP1966221A1 (en) 2005-12-22 2008-09-10 AstraZeneca AB Pyrimido- [4, 5-]-oxazines for use as dgat inhibitors
DK2402317T3 (da) 2006-03-31 2013-10-07 Novartis Ag DGAT-inhibitor
NZ572585A (en) * 2006-05-30 2011-02-25 Astrazeneca Ab 1,3,4-Oxadiazole derivatives as DGAT1 inhibitors
MX2008015228A (es) 2006-05-30 2008-12-12 Astrazeneca Ab Acido 5-fenilamino-1,3,4-oxadiazol-2-ilcarbonilamino-4-fenoxi-cicl ohexanocarboxilico sustituido como inhibidor de diacilglicerol aciltransferasa de acetil coenzima a.
ATE500251T1 (de) * 2006-06-08 2011-03-15 Astrazeneca Ab Benzimidazole und ihre verwendung zur behandlung von diabetes
CN103382174A (zh) 2006-06-23 2013-11-06 雅培制药有限公司 作为组胺h3受体调节物的环丙胺衍生物
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
WO2009024821A2 (en) * 2007-08-17 2009-02-26 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
MX2011006672A (es) * 2008-12-19 2011-07-20 Astrazeneca Ab Derivados de 1,3,4-oxadiazol y sus usos para tratar diabetes.
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
KR20120037939A (ko) * 2009-06-19 2012-04-20 아스트라제네카 아베 Ｄｇａｔ１의 억제제로서 피라진 카르복사미드
JP5883794B2 (ja) * 2009-11-05 2016-03-15 フィブロスタチン ソシエダ リミターダＦｉｂｒｏｓｔａｔｉｎ，Ｓｏｃｉｅｄａｄ Ｌｉｍｉｔａｄａ 擬似ｑ２ペプチドを用いるｇｐｂｐ抑制
TWI510241B (zh) 2010-02-18 2015-12-01 Vtv Therapeutice Llc 苯基－雜芳基衍生物及其使用方法
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
WO2012064569A1 (en) * 2010-11-08 2012-05-18 Merck Sharp & Dohme Corp. Imidazole derivatives
PT2714647E (pt) * 2011-05-23 2015-09-02 Janssen Pharmaceutica Nv Derivativos bifenil usados como antagonistas do recetor da glicagina
WO2012165398A1 (ja) * 2011-05-30 2012-12-06 第一三共株式会社 シクロアルキルオキシビアリール型化合物
WO2013068328A1 (en) * 2011-11-07 2013-05-16 Intervet International B.V. Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors
WO2013074387A1 (en) * 2011-11-14 2013-05-23 Merck Sharp & Dohme Corp. Imidazole derivatives
WO2013119040A1 (en) * 2012-02-07 2013-08-15 Kainos Medicine, Inc. Compounds as inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
MX357768B (es) * 2012-04-27 2018-07-24 Novartis Ag Inhibidores de dgat1 de eter ciclico de cabeza de puente.
WO2014089364A1 (en) 2012-12-06 2014-06-12 Quanticel Pharmaceuticals, Inc Histone demethylase inhibitors
US8962660B2 (en) 2013-03-14 2015-02-24 Bristol-Myers Squibb Company Oxabicyclo [2.2.2] acid GPR120 modulators
JP6492432B2 (ja) * 2013-07-09 2019-04-03 東ソー株式会社 アダマンチル基を有する環状アジン化合物、その製造方法、及びそれを構成成分とする有機電界発光素子
CA2931313C (en) * 2013-11-21 2022-04-05 Marquette University Substituted (4'-hydroxyphenyl)cycloalkane compounds and uses thereof as selective agonists of the estrogen receptor beta isoform
EP3177293B1 (en) * 2014-03-12 2021-05-05 Astrazeneca AB Method of treating skin conditions
BR112020025208A2 (pt) * 2018-06-21 2021-03-09 Dermavant Sciences GmbH Formulações tópicas de inibidores de dgat1 e seus métodos de uso
EP3590927A1 (en) 2018-07-05 2020-01-08 Bayer Animal Health GmbH Novel compounds for controlling arthropods
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN114286811B (zh) * 2019-04-17 2024-03-08 伊克斯切尔制药有限责任公司 富马酸单甲酯的前药

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3245989A (en) * 1962-12-15 1966-04-12 Acraf 3-aminophenyl-5-aminoloweralkyl-1, 2, 4-oxadiazoles
US4983731A (en) 1989-03-17 1991-01-08 Nebraska Department Of Economic Development Separation and purification of sugar esters
US5491172A (en) 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
IL109431A (en) 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
US20030167483A1 (en) 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
WO2000058491A1 (fr) 1999-03-25 2000-10-05 The Kitasato Institute Nouvelles substances kf-1040t4a, kf-1040t4b, kf-1040t5a et kf-1040t5b et leur procede de production
TW518218B (en) 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
GB0021670D0 (en) 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
CA2369967A1 (en) 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
JP2002284741A (ja) 2001-03-23 2002-10-03 Kitasato Inst:The ローズリピン誘導体
PT1425014E (pt) 2001-08-31 2007-03-30 Sanofi Aventis Deutschland Derivados diarilcicloalquilo, processo para a sua preparação como activadores de ppar
DE10223273A1 (de) 2002-05-24 2003-12-04 Aventis Pharma Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
NZ531853A (en) * 2001-11-01 2006-02-24 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
FR2840301B1 (fr) 2002-05-29 2007-03-23 Sanofi Synthelabo Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique
US20060004010A1 (en) 2002-07-10 2006-01-05 Hiromu Habashita Ccr4 antagonist and medical use thereof
MXPA05000053A (es) 2002-07-12 2005-04-08 Aventis Pharma Gmbh Benzoilureas heterociclicamente sustituidas, metodo para su produccion y su uso como medicamentos.
JP4164645B2 (ja) 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
US20040087590A1 (en) 2002-08-23 2004-05-06 University Of Connecticut Novel biphenyl and biphenyl-like cannabinoids
US6875784B2 (en) 2002-10-09 2005-04-05 Pharmacia & Upjohn Company Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives
WO2004032882A2 (en) 2002-10-10 2004-04-22 Smithkline Beecham Corporation Chemical compounds
MXPA05005425A (es) 2002-11-22 2005-11-23 Japan Tobacco Inc Heterociclos que contienen nitrogeno, biciclicos, fusionados.
KR101145252B1 (ko) 2003-01-08 2012-05-24 유니버시티 오브 워싱톤 항균제
WO2004089927A1 (en) 2003-04-07 2004-10-21 Cortical Pty Ltd Novel methods for the treatment of inflammatory diseases
AR044152A1 (es) 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
EP1653969A4 (en) 2003-08-07 2006-12-20 Japan Tobacco Inc PYRROLO 1,2-B PYRIDAZINE DERIVATIVES
JPWO2005023771A1 (ja) 2003-09-05 2006-11-02 小野薬品工業株式会社 ケモカインレセプターアンタゴニストおよびその医薬用途
US20050143464A1 (en) 2003-09-22 2005-06-30 Use-Techno Corporation Insulin secretion potentiator
JP4956191B2 (ja) 2003-10-17 2012-06-20 インサイト コーポレーション マトリックスメタロプロテイナーゼの阻害剤としての置換環状ヒドロキサメート
GB0325192D0 (en) 2003-10-29 2003-12-03 Astrazeneca Ab Method of use
US20050101660A1 (en) 2003-11-11 2005-05-12 The Skinny Drink Company Composition for prevention and treatment of obesity, cardiovascular and coronary artery disease
JP2005206492A (ja) 2004-01-21 2005-08-04 Sankyo Co Ltd スルホンアミド化合物
EP1718309A2 (en) 2004-01-30 2006-11-08 Japan Tobacco, Inc. Anorectic compounds
WO2006001463A1 (ja) 2004-06-23 2006-01-05 Ono Pharmaceutical Co., Ltd. Ｓ１ｐ受容体結合能を有する化合物およびその用途
AU2005260495B2 (en) 2004-07-02 2009-04-30 Sankyo Company, Limited Urea derivative
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
DE602005025517D1 (de) 2004-10-15 2011-02-03 Bayer Healthcare Llc Herstellung und anwendung von biphenyl-4-yl-carbonylaminosäurederivaten zur behandlung von obesitas
WO2006054370A1 (en) 2004-11-16 2006-05-26 Use-Techno Corporation Gluconeogenesis inhibiting agent
CA2588162A1 (en) 2004-12-14 2006-06-22 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
WO2006082952A1 (ja) 2005-02-01 2006-08-10 Takeda Pharmaceutical Company Limited アミド化合物
EP1848687A1 (en) 2005-02-07 2007-10-31 F. Hoffmann-Roche AG Inhibitors of diacylglycerol acyltransferase (dgat)
US20090215780A1 (en) 2005-04-19 2009-08-27 Bayer Pharmaceuticals Corporation Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity
CA2607121A1 (en) 2005-05-10 2006-11-16 Christophe Michoud Diacylglycerol acyltransferase inhibitors
EP1893592A1 (en) 2005-06-11 2008-03-05 AstraZeneca AB Oxadiazole derivatives as dgat inhibitors
WO2007007588A1 (ja) 2005-07-08 2007-01-18 Ono Pharmaceutical Co., Ltd. 平面性を有する環状基を母核とする化合物
CA2617055A1 (en) 2005-07-29 2007-02-08 Bayer Healthcare Llc Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
JP2007131584A (ja) 2005-11-11 2007-05-31 Sankyo Co Ltd 新規ベンゾオキサゾール誘導体
BRPI0619052A2 (pt) 2005-11-28 2011-09-20 Hoffmann La Roche compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de diacilglicerol aciltransferase, e seu uso
JP2007191471A (ja) 2005-12-21 2007-08-02 Sankyo Co Ltd ウレア誘導体を含有する医薬
EP1966221A1 (en) 2005-12-22 2008-09-10 AstraZeneca AB Pyrimido- [4, 5-]-oxazines for use as dgat inhibitors
WO2007074753A1 (ja) 2005-12-27 2007-07-05 Daiichi Sankyo Company, Limited 置換されたウレア誘導体を含有する医薬
DK2402317T3 (da) * 2006-03-31 2013-10-07 Novartis Ag DGAT-inhibitor
US8088776B2 (en) 2006-04-21 2012-01-03 Eli Lilly And Company Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
US20080064717A1 (en) 2006-05-19 2008-03-13 Rajesh Iyengar Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
WO2007137103A2 (en) 2006-05-19 2007-11-29 Abbott Laboratories Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
MX2008015228A (es) 2006-05-30 2008-12-12 Astrazeneca Ab Acido 5-fenilamino-1,3,4-oxadiazol-2-ilcarbonilamino-4-fenoxi-cicl ohexanocarboxilico sustituido como inhibidor de diacilglicerol aciltransferasa de acetil coenzima a.
NZ572585A (en) * 2006-05-30 2011-02-25 Astrazeneca Ab 1,3,4-Oxadiazole derivatives as DGAT1 inhibitors
JP2009539816A (ja) * 2006-06-06 2009-11-19 アストラゼネカ アクチボラグ 化学化合物
ATE500251T1 (de) 2006-06-08 2011-03-15 Astrazeneca Ab Benzimidazole und ihre verwendung zur behandlung von diabetes
GB0611506D0 (en) * 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
GB0611507D0 (en) 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
GB0611552D0 (en) 2006-06-12 2006-07-19 Astrazeneca Ab Chemical compounds
EP2044055A4 (en) 2006-07-21 2011-03-23 Takeda Pharmaceutical amide compounds
WO2008011130A2 (en) 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
US7569590B2 (en) 2006-09-19 2009-08-04 Bristol-Myers Squibb Company Use of thianecarboxamides as dgat inhibitors
KR100811100B1 (ko) 2006-09-27 2008-03-06 한국생명공학연구원 벤즈아졸 유도체를 유효성분으로 함유하는 대사성 질환예방 및 치료용 약학적 조성물
KR100795462B1 (ko) 2006-09-27 2008-01-16 한국생명공학연구원 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물
MX2009003222A (es) 2006-10-04 2009-04-06 Hoffmann La Roche Derivados de 3-piridinocarboxamida y 2-pirazinocarboxamida como agentes elevadores de colesterol de lipoproteina de alta densidad.
EP2084146B1 (en) 2006-10-04 2013-08-21 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
PE20080888A1 (es) 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
WO2008046216A1 (en) 2006-10-18 2008-04-24 Methylgene, Inc. Kinase inhibitors and uses thereof
CA2668744C (en) 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
EP2117526B1 (en) 2006-11-29 2013-04-03 Abbott Laboratories Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
EP2101783A2 (en) 2006-12-11 2009-09-23 Novartis Ag Method of preventing or treating myocardial ischemia
US20100093733A1 (en) 2007-02-15 2010-04-15 Prosidion Limited Amide and urea derivatives for the treatment of metabolic diseases
GB0707662D0 (en) 2007-04-20 2007-05-30 Astrazeneca Ab Chemical compounds
NZ580660A (en) 2007-04-30 2012-02-24 Abbott Lab Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
US8058299B2 (en) 2007-05-22 2011-11-15 Via Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
JP2010132590A (ja) 2008-12-03 2010-06-17 Astellas Pharma Inc オキサジアゾール化合物
MX2011006672A (es) 2008-12-19 2011-07-20 Astrazeneca Ab Derivados de 1,3,4-oxadiazol y sus usos para tratar diabetes.

Also Published As

Publication number Publication date
US20120108602A1 (en) 2012-05-03
BRPI0821274A2 (pt) 2017-06-13
CN101932562B (zh) 2013-06-12
IL206045A0 (en) 2010-11-30
ZA201003979B (en) 2011-11-30
KR20100099738A (ko) 2010-09-13
EP2234978A1 (en) 2010-10-06
US7994179B2 (en) 2011-08-09
EP2234978B1 (en) 2015-02-25
EA201001015A1 (ru) 2011-02-28
PE20091682A1 (es) 2009-12-04
AU2008339570A1 (en) 2009-07-02
TW200932235A (en) 2009-08-01
CL2008003847A1 (es) 2009-11-27
CA2707660A1 (en) 2009-07-02
NI201000108A (es) 2012-05-14
JP2011507823A (ja) 2011-03-10
AU2008339570B2 (en) 2012-04-12
ECSP10010274A (es) 2010-07-30
CR11518A (es) 2010-07-15
NZ586104A (en) 2012-02-24
AR069802A1 (es) 2010-02-17
CN101932562A (zh) 2010-12-29
WO2009081195A1 (en) 2009-07-02
ES2535083T3 (es) 2015-05-05
DOP2010000192A (es) 2010-07-15
JP5662803B2 (ja) 2015-02-04
US20090298853A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
CO6290685A2 (es) Compuestos de carbamoilo como inhibidores de la dgat1 190
ECSP10010060A (es) Derivados de pirazol sustituídos
AR063028A1 (es) Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
TW200637559A (en) 3-propenylcefem derivative
AR064736A1 (es) Agonistas de gpcr
NZ601220A (en) Hepatitis c virus inhibitors
DE602005027213D1 (de) Neue imidazolidinderivate
CY1109222T1 (el) Παραγωγο συγχωνευμενης κινολινης και χρηση του
CR9267A (es) Derivados de quinazolina para el tratamiento de la tuberculosis latente
CO5690607A2 (es) Compuestos de piridina como inhibidores de dipeptidil peptidasa iv
AR066882A1 (es) Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato.
ES2531009T3 (es) Análogos sustituidos de dicetopiperazina para su uso como agentes para la administración de fármacos
AR061548A1 (es) 3-aminopirrolidino-4-lactamas sustituidas como inhibidoras de dipeptidilpeptidasa iv (dpp-iv), composiciones farmaceuticas que las comprenden y el uso de las mismas en el tratamiento de la diabetes ii.
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
AR065854A1 (es) Derivados de 1-oxa-3,9-diaza-espiro[5.5]undecan-2-ona,medicamentos que los contienen y usos como agentes anti vih,entre otros.
PE20011166A1 (es) Piridinas, pirimidinas, purinonas, pirrolopirimidinonas y pirrolopiridinonas como antagonistas del factor liberador de corticotropina
AR074608A1 (es) Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas
AR063805A1 (es) Derivados de triazol sustituidos como inhibidores de ksp. composiciones farmaceuticas.
EA201170595A1 (ru) ПРОИЗВОДНОЕ ФЕНАНТРОИНДОЛИЗИДИНА И ИНГИБИТОР NFkB, СОДЕРЖАЩИЙ ЕГО В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА
TW200600085A (en) External preparation
RS53389B (en) PHARMACEUTICAL UNITS
MY197742A (en) Morphinan derivative
AR053835A1 (es) Tetrahidropiridoazepin - 8 - onas como moduladores del receptor de dopamina d2 y compuestos relacionados para el tratamiento de la esquizofrenia y otros trastornos del snc, composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos.
EA201170596A1 (ru) ФЕНАНТРОИНДОЛИЗИДИНОВОЕ СОЕДИНЕНИЕ И ИНГИБИТОР NFkB, СОДЕРЖАЩИЙ ЕГО В КАЧЕСТВЕ ДЕЙСТВУЮЩЕГО ИНГРЕДИЕНТА
MX2009002685A (es) Derivados de acetamida de (2- (1-oxo-1h-isoquinolin-2-il).

Legal Events

Date Code Title Description
FC Application refused